AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7951338 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 1810
Study 7951338 — intervention group
Group type: COMPARATOR
Intervention: No specific treatment
Number of subjects: 1810
Study 7951338 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1810
Study 2959208 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised ipratropium
Number of subjects: 37
Study 2959208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 2108911 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole plus colistin with nonabsorbable antimycotics
Number of subjects: 0
Study 2108911 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin with nonabsorbable antimycotics
Number of subjects: 0
Study 2108911 — intervention group
Group type: COMPARATOR
Intervention: Cotrimoxazole
Number of subjects: 0
Study 2108911 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole plus colistin and ciprofloxacin
Number of subjects: 0
Study 2108911 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin
Number of subjects: 0
Study 1080266 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg methylergonovine maleate (Methergine) intramuscularly
Number of subjects: 29
Study 1080266 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 29
Study 31068125 — intervention group
Group type: EXPERIMENTAL
Intervention: Message 1 (depression can happen to anyone)
Number of subjects: 1957
Study 31068125 — intervention group
Group type: EXPERIMENTAL
Intervention: Message 2 (depression needs treatment)
Number of subjects: 1957
Study 31068125 — intervention group
Group type: EXPERIMENTAL
Intervention: Message 3 (depression improves with treatment)
Number of subjects: 1957
Study 31068125 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional responses to Message 2
Number of subjects: 1957
Study 31068125 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional responses to Message 3
Number of subjects: 1957
Study 28182335 — intervention group
Group type: EXPERIMENTAL
Intervention: Ductus venosus (DV) monitoring
Number of subjects: 317
Study 28182335 — intervention group
Group type: COMPARATOR
Intervention: CTG-STV monitoring
Number of subjects: 317
Study 26050057 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm blood pressure measurement at 0° backrest elevation
Number of subjects: 30
Study 26050057 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle blood pressure measurement at 0° backrest elevation
Number of subjects: 30
Study 26050057 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm blood pressure measurement at 30° backrest elevation
Number of subjects: 30
Study 26050057 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle blood pressure measurement at 30° backrest elevation
Number of subjects: 30
Study 26050057 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic BP correlation for participants without ankle edema
Number of subjects: 30
Study 26050057 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic BP correlation for participants with ankle edema
Number of subjects: 30
Study 23182660 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m2)
Number of subjects: 211
Study 23182660 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m2)
Number of subjects: 211
Study 21722898 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU)
Number of subjects: 59
Study 21722898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 19381735 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (2.4 billion colonies of Lactobacillus administered daily postoperatively)
Number of subjects: 44
Study 19381735 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 44
Study 19381735 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 44
Study 16769056 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 104
Study 16769056 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 104
Study 16769056 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 104
Study 14679122 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan (180 mg/m²) with 5‐fluorouracil (400 mg/m² bolus) and leucovorin (125 mg/m²) followed by 5‐FU (1200 mg/m² infusion over 48 h) every 2 weeks
Number of subjects: 40
Study 14679122 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan and 5‐fluorouracil treatment
Number of subjects: 40
Study 11716046 — intervention group
Group type: EXPERIMENTAL
Intervention: 21-gauge needles
Number of subjects: 50
Study 11716046 — intervention group
Group type: COMPARATOR
Intervention: 25-gauge needles
Number of subjects: 50
Study 11716046 — intervention group
Group type: EXPERIMENTAL
Intervention: 21-gauge and 25-gauge needles
Number of subjects: 50
Study 9150480 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA) treatment
Number of subjects: 19
Study 9150480 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine A (CsA) treatment
Number of subjects: 19
Study 7950184 — intervention group
Group type: EXPERIMENTAL
Intervention: Kuiyangqing Pill (KYQP) for EHS group
Number of subjects: 80
Study 7950184 — intervention group
Group type: COMPARATOR
Intervention: Bismuth aluminate tablets (control) for EHS group
Number of subjects: 80
Study 7950184 — intervention group
Group type: EXPERIMENTAL
Intervention: Kuiyangqing Pill (KYQP) for DCS group
Number of subjects: 80
Study 7950184 — intervention group
Group type: COMPARATOR
Intervention: Bismuth aluminate tablets (control) for DCS group
Number of subjects: 80
Study 3109990 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 micrograms of rioprostil
Number of subjects: 8
Study 3109990 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 micrograms of rioprostil
Number of subjects: 8
Study 3109990 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 micrograms of rioprostil
Number of subjects: 8
Study 3109990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3109990 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of rioprostil
Number of subjects: 8
Study 29218735 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibre Retention Osseous Resective Surgery (FibReORS)
Number of subjects: 13
Study 29218735 — intervention group
Group type: COMPARATOR
Intervention: Osseous Resective Surgery (ORS)
Number of subjects: 13
Study 28695586 — intervention group
Group type: EXPERIMENTAL
Intervention: Alveolar recruitment group (pressure-controlled ventilation set at 16 cmH2 O with 10 cmH2 O positive end-expiratory pressure)
Number of subjects: 30
Study 28695586 — intervention group
Group type: COMPARATOR
Intervention: Control group (volume-controlled ventilation with 5 cmH2 O positive end-expiratory pressure, low tidal volumes)
Number of subjects: 30
Study 28695586 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 24972907 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical case management (CM) programme
Number of subjects: 150
Study 24972907 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment programme (STP)
Number of subjects: 150
Study 23296827 — intervention group
Group type: EXPERIMENTAL
Intervention: Tannin diet (20 g DM of alfalfa hay/kg BW supplemented with 50 g of quebracho/kg DM)
Number of subjects: 16
Study 23296827 — intervention group
Group type: COMPARATOR
Intervention: Control diet (20 g DM of alfalfa hay/kg BW)
Number of subjects: 16
Study 23296827 — intervention group
Group type: EXPERIMENTAL
Intervention: Tannin diet
Number of subjects: 16
Study 23296827 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 16
Study 21723792 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel and Bevacizumab (PB)
Number of subjects: 187
Study 21723792 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel, Bevacizumab, and Gemcitabine (PB+G)
Number of subjects: 187
Study 19491981 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspherical IOLs (Acrysof IQ, Tecnis Z9001)
Number of subjects: 57
Study 19491981 — intervention group
Group type: COMPARATOR
Intervention: Spherical IOL (Acrysof Natural)
Number of subjects: 57
Study 19491981 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrysof IQ and Tecnis Z9001
Number of subjects: 57
Study 17111014 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAFF; 5 mg/kg body mass)
Number of subjects: 18
Study 15679253 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and its derivatives with radiation therapy
Number of subjects: 0
Study 11543992 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol group (alcoholic drink)
Number of subjects: 61
Study 11543992 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo group (non-alcoholic drink told to contain alcohol)
Number of subjects: 61
Study 11543992 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-alcoholic drink told to contain no alcohol)
Number of subjects: 61
Study 9485982 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (1 mg.kg‐1)
Number of subjects: 0
Study 9485982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9485982 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (0.09 mg.kg‐1)
Number of subjects: 0
Study 9485982 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 0
Study 8203424 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified biophysical profile
Number of subjects: 2774
Study 8203424 — intervention group
Group type: COMPARATOR
Intervention: Contraction stress test
Number of subjects: 2774
Study 8203424 — intervention group
Group type: COMPARATOR
Intervention: Biophysical profile
Number of subjects: 2774
Study 3540140 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglycoside therapy (gentamicin, tobramycin, amikacin)
Number of subjects: 236
Study 3540140 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated maximal and mean peak aminoglycoside concentration/MIC ratios
Number of subjects: 236
Study 3540140 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal peak concentration/MIC ratio
Number of subjects: 236
Study 3540140 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak concentration/MIC ratios
Number of subjects: 236
Study 30544227 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi intervention
Number of subjects: 41
Study 30691515 — intervention group
Group type: EXPERIMENTAL
Intervention: Triangulating Stapling (TS) method
Number of subjects: 125
Study 30691515 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional End-to-End Stapling (FEES) method
Number of subjects: 125
Study 30691515 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall postoperative morbidity
Number of subjects: 125
Study 30691515 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of anastomotic leakage, aspiration pneumonia, or reflux esophagitis
Number of subjects: 125
Study 30691515 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life assessment using FACT-E
Number of subjects: 125
Study 29030199 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 μg iodine orally once a day until delivery
Number of subjects: 832
Study 29030199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 832
Study 26319820 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, phytosterol-supplemented milk (2.24 gr of plant sterols daily)
Number of subjects: 67
Study 26319820 — intervention group
Group type: COMPARATOR
Intervention: Low-fat conventional milk
Number of subjects: 67
Study 23810643 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mL of beer
Number of subjects: 17
Study 23810643 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mL of dealcoholized beer
Number of subjects: 17
Study 23810643 — intervention group
Group type: EXPERIMENTAL
Intervention: 67 mL of vodka and 733 mL water
Number of subjects: 17
Study 23810643 — intervention group
Group type: COMPARATOR
Intervention: Control (water)
Number of subjects: 17
Study 21343498 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 44
Study 21343498 — intervention group
Group type: COMPARATOR
Intervention: IFN
Number of subjects: 44
Study 18826157 — intervention group
Group type: EXPERIMENTAL
Intervention: Shen Shuai Fang + western medicine
Number of subjects: 125
Study 18826157 — intervention group
Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 125
Study 16874591 — intervention group
Group type: EXPERIMENTAL
Intervention: Barefoot training
Number of subjects: 63
Study 16874591 — intervention group
Group type: EXPERIMENTAL
Intervention: Ski boot training
Number of subjects: 63
Study 16874591 — intervention group
Group type: COMPARATOR
Intervention: Control group (ankle brace)
Number of subjects: 63
Study 15213369 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. netilmicin every 24 h (initially), then every 48 h for safety in premature group
Number of subjects: 80
Study 10868311 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) interferon alfa‐n3 (10 million units)
Number of subjects: 6
Study 10868311 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (i.m.) interferon alfa‐n3 (10 million units)
Number of subjects: 6
Study 10868311 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SQ) interferon alfa‐n3 (10 million units)
Number of subjects: 6
Study 10868311 — intervention group
Group type: EXPERIMENTAL
Intervention: All routes (i.v., i.m., SQ)
Number of subjects: 6
Study 9116382 — intervention group
Group type: EXPERIMENTAL
Intervention: Talking periods (stress and relaxation)
Number of subjects: 42
Study 9116382 — intervention group
Group type: COMPARATOR
Intervention: Initial 11-minute silent period
Number of subjects: 42
Study 9116382 — intervention group
Group type: COMPARATOR
Intervention: Silent period
Number of subjects: 42
Study 1417314 — intervention group
Group type: EXPERIMENTAL
Intervention: Endolymphatic administration of kanamycin
Number of subjects: 0
Study 1417314 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular administration of kanamycin
Number of subjects: 0
Study 1417314 — intervention group
Group type: COMPARATOR
Intervention: Lymphotropic administration of kanamycin
Number of subjects: 0
Study 1417314 — intervention group
Group type: EXPERIMENTAL
Intervention: Endolymphatic therapy during postoperative period
Number of subjects: 0
Study 6519841 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 20 mg, four times a day for 3 weeks
Number of subjects: 12
Study 6519841 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg, four times a day for 3 weeks
Number of subjects: 12
Study 6519841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30383495 — intervention group
Group type: EXPERIMENTAL
Intervention: IDegLira (insulin degludec/liraglutide)
Number of subjects: 344
Study 30383495 — intervention group
Group type: COMPARATOR
Intervention: Basal insulin
Number of subjects: 344
Study 30383495 — intervention group
Group type: COMPARATOR
Intervention: Unchanged GLP-1RA
Number of subjects: 344
Study 29791247 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-support intervention delivered by the interprofessional ICU team
Number of subjects: 1420
Study 26093599 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydroepiandrosterone (DHEA) 100 mg
Number of subjects: 55
Study 26093599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 23589465 — intervention group
Group type: EXPERIMENTAL
Intervention: (129) Xe MRI
Number of subjects: 7
Study 23589465 — intervention group
Group type: EXPERIMENTAL
Intervention: (3) He MRI
Number of subjects: 7
Study 23589465 — intervention group
Group type: EXPERIMENTAL
Intervention: (129) Xe MRI COV
Number of subjects: 7
Study 23589465 — intervention group
Group type: EXPERIMENTAL
Intervention: (3) He MRI COV
Number of subjects: 7
Study 21339413 — intervention group
Group type: EXPERIMENTAL
Intervention: Early appendectomy (within 24 hours of admission)
Number of subjects: 131
Study 21339413 — intervention group
Group type: COMPARATOR
Intervention: Interval appendectomy (6-8 weeks after diagnosis)
Number of subjects: 131
Study 21339413 — intervention group
Group type: EXPERIMENTAL
Intervention: Early appendectomy
Number of subjects: 131
Study 21339413 — intervention group
Group type: COMPARATOR
Intervention: Interval appendectomy
Number of subjects: 131
Study 19118791 — intervention group
Group type: EXPERIMENTAL
Intervention: Low back pain (LBP) group
Number of subjects: 13
Study 19118791 — intervention group
Group type: COMPARATOR
Intervention: Control group (without LBP)
Number of subjects: 13
Study 18039102 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell-based cardiac repair
Number of subjects: 0
Study 18039102 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell-based strategies
Number of subjects: 0
Study 15054445 — intervention group
Group type: EXPERIMENTAL
Intervention: Haematopoietic growth factors (HGF) plus chemotherapy
Number of subjects: 779
Study 15054445 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 779
Study 11430781 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial weight for height (WHZ) score
Number of subjects: 141
Study 11430781 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial height for age (HAZ) score
Number of subjects: 141
Study 11430781 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower leg length growth
Number of subjects: 141
Study 11430781 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in HAZ
Number of subjects: 141
Study 11430781 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial WHZ score and maternal height
Number of subjects: 141
Study 9672452 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (6 mg)
Number of subjects: 22
Study 9672452 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 9626025 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 24 micrograms twice daily
Number of subjects: 72
Study 9626025 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 12 micrograms once daily
Number of subjects: 72
Study 9626025 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 6 micrograms twice daily
Number of subjects: 72
Study 9626025 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline 500 micrograms four times daily
Number of subjects: 72
Study 9626025 — intervention group
Group type: EXPERIMENTAL
Intervention: All formoterol regimens
Number of subjects: 72
Study 9626025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 1756022 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 0
Study 1756022 — intervention group
Group type: COMPARATOR
Intervention: Tissue plasminogen activator
Number of subjects: 0
Study 7051826 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 30
Study 7051826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31792263 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS over the mPFC
Number of subjects: 60
Study 31792263 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 60
Study 29490640 — intervention group
Group type: EXPERIMENTAL
Intervention: 2, 5 or 8 FV portions/day for 4 weeks
Number of subjects: 30
Study 26718065 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral intravenous cannulae (PIVC) inserted
Number of subjects: 357
Study 24275895 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment for depression
Number of subjects: 0
Study 21075578 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine and ultra-low-dose naltrexone
Number of subjects: 0
Study 21075578 — intervention group
Group type: COMPARATOR
Intervention: Morphine alone (with placebo)
Number of subjects: 0
Study 20207004 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting skills training (2-hour weekly sessions for 2 weeks)
Number of subjects: 224
Study 20207004 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 224
Study 18398641 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic adrenalectomy (n = 13)
Number of subjects: 22
Study 18398641 — intervention group
Group type: COMPARATOR
Intervention: Open adrenalectomy (n = 9)
Number of subjects: 22
Study 15816462 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (500 mg/body) in saline 2 hours before surgery
Number of subjects: 40
Study 15816462 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline alone)
Number of subjects: 40
Study 12166555 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (5 mg) and Loratadine (10 mg)
Number of subjects: 19
Study 12166555 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (5 mg)
Number of subjects: 19
Study 12166555 — intervention group
Group type: COMPARATOR
Intervention: Loratadine (10 mg)
Number of subjects: 19
Study 12166555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 9672052 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 291
Study 9672052 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 291
Study 8092839 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomefloxacin 400 mg once daily for 14 days
Number of subjects: 133
Study 8092839 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole 160/800 mg twice daily for 14 days
Number of subjects: 133
Study 8092839 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 133
Study 8092839 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 133
Study 3041830 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin
Number of subjects: 111
Study 3041830 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular cefamandole
Number of subjects: 111
Study 29633268 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix (ADM)
Number of subjects: 40
Study 29633268 — intervention group
Group type: COMPARATOR
Intervention: Subepithelial connective tissue graft (sCTG)
Number of subjects: 40
Study 27999758 — intervention group
Group type: EXPERIMENTAL
Intervention: GPC3 peptide vaccine
Number of subjects: 32
Study 27999758 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (control)
Number of subjects: 32
Study 24986956 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.125 mM
Number of subjects: 0
Study 24986956 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.250 mM
Number of subjects: 0